|
Synonyms: IDEC-2B8 | IDEC-Y2B8-yttrium ibritumomab tiuxetan | NSC-715848 | Zevalin®
ibritumomab tiuxetan is an approved drug (FDA (2002), EMA (2004))
Compound class:
Antibody
Comment: A monoclonal antibody used as a radioimmunotherapy treatment.
|
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| non-Hodgkin lymphoma |
Disease Ontology:
DOID:0060060 OMIM: 605027 |
Approved specifically for relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma can be treated with Yttrium-90 labelled ibritumomab tiuxetan. | |
